The CLASP II D trial aimed to assess the PASCAL Transcatheter Valve Repair System in patients with degenerative mitral regurgitation at risk for surgery. In this touchCARDIO interview, we speak with Dr Scott Lim (The University of Virginia, Charlottesville, VA, USA) to discuss the Edwards PASCAL Transcatheter Valve Repair System and the outcomes of the CLASP II D clinical trial.
The abstract entitled ‘CLASP II D Trial: A Randomized Comparison of Transcatheter Edge-to-Edge Repair Devices for Degenerative Mitral Regurgitation – Clinical Outcomes and Echo Findings’ was presented at the Transcatheter Cardiovascular Therapeutics (TCT) conference, 16 – 19, September 2022.
Questions:
- What is the prognosis for patients with degenerative mitral regurgitation and a prohibitive risk for mitral valve surgery? (0:19)
- Could you give us a brief overview of the Edwards PASCAL Transcatheter Valve Repair System? (1:02)
- What were the aims, design and eligibility criteria of the CLASP II D clinical trial? (2:59)
- What were the primary and secondary outcome measures, and how well were they achieved? (3:46)
- What are the clinical implications of these findings? (5:35)
Disclosures: Scott Lim is on the advisory board for Philips and is a consultant for Ancora, Valgen and Venus. He has received grant/research support from Abbott, Boston Scientific, Edwards Lifesciences and Medtronic.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Danielle Crosby.
Filmed as a highlight of TCT 2022
Access more content on Devices here
